Phaseline

Targets › RYR1

RYR1 (Ryanodine receptor 1): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Neurology; next expected readout Jan 2027.

Cytosolic calcium-activated calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytosol and thereby plays a key role in triggering muscle contraction following depolarization of T-tubules. Repeated very high-level exercise increases the open probability of the channel and leads to Ca(2+) leaking into the cytoplasm. (UniProt, P21817)

Open in Phaseline: the race on RYR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RyCarma TherapeuticsSurlorian (ARM210, S48168)
Ryanodine receptor 1 (RYR1) activator
RYR1Phase 2Autosomal Dominant RYR1-Related MyopathyAug 2027
National Institute of Allergy and Infectious Diseases (NIAID)Dantrolene
Ryanodine receptor antagonist
RYR1Phase 1Multiple SclerosisJan 2027

Conditions

Autosomal Dominant RYR1-Related Myopathy (1) Multiple Sclerosis (1)

Modalities

small molecule (2)

Companies

RyCarma Therapeutics (1) National Institute of Allergy and Infectious Diseases (NIAID) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.